Literature DB >> 7876193

Endogenous cleavage of phospholipase C-beta 3 by agonist-induced activation of calpain in human platelets.

Y Banno1, S Nakashima, T Hachiya, Y Nozawa.   

Abstract

Two membrane-associated phosphoinositide-specific phospholipase Cs (mPI-PLC-1 and mPI-PLC-2) and a cytosolic enzyme (cPI-PLC) that were activated by brain G-protein beta gamma subunits have been isolated from human platelets. The truncation of mPI-PLC-1 that was mediated by mu-calpain induced much higher activation by beta gamma subunits (Banno, Y., Asano, T., and Nozawa, Y. (1994) FEBS Lett. 340, 185-188). On the basis of size and immunological cross-reactivity, mPI-PLC-1 (155 kDa) was PLC-beta 3, and mPI-PLC-2 (100 kDa) was its truncated form. The cPI-PLC (140 kDa) was recognized by the antibody selective for internal sequences of PLC-beta 3 but not by the antibody raised against its carboxyl terminus, indicating that it may be related to PLC-beta 3. Treatment of human platelets with A23187 and dibucaine, activators of calpain, caused cleavage of actin-binding protein and talin in a time-dependent manner. At the same time, decrease of PLC-beta 3 (155 and 140 kDa) and concomitant increase of the 100-kDa product of cleavage were observed on immunoblots with the antibody to internal sequences of PLC-beta 3. Furthermore, stimulation of platelets by natural agonists, thrombin and collagen, caused the cleavage of PLC-beta 3 (155 and 140 kDa) and an increase of 100 kDa PLC-beta 3 in a time- and dose-dependent manner. The cleavage of these PLC-beta 3 enzymes was completely blocked by calpain inhibitor, calpeptin, indicating that the PLC-beta 3 modification may be a consequence of platelet activation leading to activation of calpain. This is the first demonstration that PLC-beta 3 is indeed cleaved by calpain upon platelet activation by physiological agonists. The cleavage of PLC-beta 3 evoked by thrombin and collagen but not ADP was correlated with irreversible aggregation, suggesting that the PLC-beta 3 modification may play a role in secondary irreversible aggregation in agonist-stimulated human platelets.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7876193     DOI: 10.1074/jbc.270.9.4318

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  α-Synuclein increases the cellular level of phospholipase Cβ1.

Authors:  Yuanjian Guo; Barbara Rosati; Suzanne Scarlata
Journal:  Cell Signal       Date:  2012-01-20       Impact factor: 4.315

Review 2.  Tear me down: role of calpain in the development of cardiac ventricular hypertrophy.

Authors:  Cam Patterson; Andrea L Portbury; Jonathan C Schisler; Monte S Willis
Journal:  Circ Res       Date:  2011-08-05       Impact factor: 17.367

3.  The role of phospholipase Cβ on the plasma membrane and in the cytosol: How modular domains enable novel functions.

Authors:  Suzanne Scarlata
Journal:  Adv Biol Regul       Date:  2019-07-29

4.  Effects of Clostridium difficile toxin A and toxin B on phospholipase D activation in human promyelocytic leukemic HL60 cells.

Authors:  K Ohguchi; Y Banno; S Nakashima; N Kato; K Watanabe; D M Lyerly; Y Nozawa
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

5.  Thrombin activation of human platelets dissociates a complex containing gelsolin and actin from phosphatidylinositide-specific phospholipase Cgamma1.

Authors:  J J Baldassare; P A Henderson; A Tarver; G J Fisher
Journal:  Biochem J       Date:  1997-05-15       Impact factor: 3.857

Review 6.  Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?

Authors:  Andrew F Teich; Ottavio Arancio
Journal:  Biochem J       Date:  2012-09-01       Impact factor: 3.857

Review 7.  Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration.

Authors:  P S Vosler; C S Brennan; J Chen
Journal:  Mol Neurobiol       Date:  2008-08-07       Impact factor: 5.590

8.  Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease.

Authors:  Fabrizio Trinchese; Mauro Fa'; Shumin Liu; Hong Zhang; Ariel Hidalgo; Stephen D Schmidt; Hisako Yamaguchi; Narihiko Yoshii; Paul M Mathews; Ralph A Nixon; Ottavio Arancio
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

9.  Calpain inhibitors: a treatment for Alzheimer's disease.

Authors:  Gabriella Di Rosa; Tatjana Odrijin; Ralph A Nixon; Ottavio Arancio
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

Review 10.  Calpain-mediated regulation of platelet signaling pathways.

Authors:  Shafi M Kuchay; Athar H Chishti
Journal:  Curr Opin Hematol       Date:  2007-05       Impact factor: 3.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.